0001127602-15-028793.txt : 20151007 0001127602-15-028793.hdr.sgml : 20151007 20151007170521 ACCESSION NUMBER: 0001127602-15-028793 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20151005 FILED AS OF DATE: 20151007 DATE AS OF CHANGE: 20151007 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Alkermes plc. CENTRAL INDEX KEY: 0001520262 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 981007018 FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 BUSINESS PHONE: 00-353-1-772-8000 MAIL ADDRESS: STREET 1: CONNAUGHT HOUSE STREET 2: 1 BURLINGTON ROAD CITY: DUBLIN 4 STATE: L2 ZIP: 00000 FORMER COMPANY: FORMER CONFORMED NAME: ANTLER SCIENCE TWO PLC DATE OF NAME CHANGE: 20110804 FORMER COMPANY: FORMER CONFORMED NAME: Antler Science Two Ltd DATE OF NAME CHANGE: 20110509 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Cooke Shane CENTRAL INDEX KEY: 0001524823 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35299 FILM NUMBER: 151149492 MAIL ADDRESS: STREET 1: TREASURY BUILDING LOWER GRAND CANAL ST. CITY: DUBLIN 2 STATE: L2 ZIP: 00000 4 1 form4.xml PRIMARY DOCUMENT X0306 4 2015-10-05 0001520262 Alkermes plc. ALKS 0001524823 Cooke Shane CONNAUGHT HOUSE 1 BURLINGTON ROAD DUBLIN 4 IRELAND 1 President, Alkermes plc Ordinary Shares 2015-10-05 4 M 0 12500 0 A 53140 D Ordinary Shares 2015-10-05 4 F 0 6500 59.77 D 46640 D Ordinary Shares 2015-10-05 4 A 0 7500 0 A 54140 D Ordinary Shares 2015-10-05 4 F 0 3900 59.77 D 50240 D Restricted Stock Unit Award 0 2015-10-05 4 M 0 12500 0 D Ordinary Shares 12500 0 D Performance Restricted Stock Units 2015-10-05 4 A 0 7500 0 A Ordinary Shares 7500 7500 D This RSU award is fully vested in accordance with its terms. Each performance restricted stock unit represents a contingent right to receive one ordinary share of Alkermes plc. Represents the earned but unvested portion of the performance restricted stock units granted to the reporting person on March 3, 2014. Fifty percent of the earned performance restricted stock units vested on October 5, 2015 and are included in Table I of this Form 4; the remaining fifty percent of the earned performance restricted stock units are included in Table II of this Form 4 and will vest on October 5, 2016. The performance restricted stock units were earned based on the Food and Drug Administration's approval of ARISTADA? (aripiprazole lauroxil). /s/ Jennifer Baptiste, attorney-in-fact for Shane Cooke 2015-10-07